Ca–Mg-IP-6 and Inositol Topical Composition for Skin Ailments
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
There is a lack of information on the topical use of inositol hexakisphosphate (IP-6) and its derivatives for treating skin ailments such as erythema, eczema, psoriasis, melanoma, and other skin conditions, and their safety and efficacy in humans are not well understood.
Innovation Solution
Topical application of a composition comprising Ca—Mg-IP-6 and inositol in a 1:1 molar ratio, or a therapeutically effective amount of IP-6 and inositol derivatives, ranging from 0.1% to 10% by weight, for treating skin conditions like erythema, eczema, psoriasis, melanoma, and other skin ailments.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If topical application of IP-6 and inositol is used to treat skin ailments, then therapeutic effectiveness is improved, but safety and efficacy data are insufficient
Solution Approach 1:
The patent performs preliminary safety and efficacy testing on human subjects before widespread clinical use. The invention includes controlled studies where IP-6 and inositol compositions are applied topically to treat various skin conditions, systematically collecting data on both therapeutic effects and safety profiles to establish reliable usage guidelines
2Reliability
If a composition containing IP-6 and inositol is applied topically, then treatment of skin conditions is achieved, but the composition complexity increases
Solution Approach 1:
The patent combines IP-6 and inositol into a single topical composition that can be applied together to treat skin conditions. This merging of two active ingredients into one formulation simplifies the treatment regimen while maintaining the synergistic therapeutic effects of both compounds for conditions like melanoma, psoriasis, and eczema
Data Source
AI summary
The present invention relates to methods and compositions for treating mammalian cells and tissues for erythema, superficial (1st degree) thermal burns, eczema, psoriasis, and other skin ailments including skin rashes, poison ivy, melanoma, carcinoma including basal cell carcinoma, actinic keratosis, ageing-related damages, sun exposure-related damage, red or irritated skin, leukoderma, melasma, shingles, appearance of wrinkles. Compositions of the invention include inositol hexakisphosphate (IP-6) with or without inositol, and pharmaceutically acceptable salts thereof including Ca—Mg-IP6, for topical administration.